Home › Mining technology › Chrysos (ASX:C79)

Chrysos builds PhotonAssay momentum with 51 units deployed

Mining technology By Victor Sage 4 min read

Chrysos Corporation (ASX:C79) has reported a strong opening four months of FY27, with unaudited revenue up 27% and PhotonAssay sample volumes up 43%. The company reaffirmed its full-year guidance while expanding its deployed fleet and contracted pipeline.

  • Unaudited July to October revenue of A$36.7 million, up 27% year on year
  • 4.91 million samples processed, including a record 1.36 million in October
  • Deployed PhotonAssay fleet reaches 51 units across five continents
  • 97 units contracted after 15 new lease agreements in FY27
  • FY27 revenue guidance of A$108 million to A$118 million reaffirmed

PhotonAssay volumes accelerate into FY27

Chrysos Corporation (ASX:C79) has started FY27 with the kind of operating momentum that makes its unchanged guidance look deliberately cautious. Unaudited revenue for July to October reached A$36.7 million, up 27% from the same period last year, while 4.91 million PhotonAssay samples were processed, an increase of 43%.

Image © Chrysos Corporation Limited. From “Pre AGM Trading Update Presentation”, 19 Nov 2026.

October delivered a monthly record of 1.36 million samples. Chrysos said monthly throughput has grown between 36% and 48% in FY27 to date, with the deployed fleet sustaining more than 90% average availability despite high utilisation. Additional Assay Charges contributed A$13.7 million of the period's revenue, or 38% of PhotonAssay revenue, up from 26% a year earlier. Minimum Monthly Assay Payments contributed A$22.6 million, with A$0.3 million in other revenue.

Fleet expansion builds on contracted demand

The company has deployed six units in FY27, taking its operating fleet to 51 across five continents. A further six units are currently being deployed, including installations for Newmont, ALS, SGS, Bureau Veritas and other laboratory and mining customers. Seven newly manufactured units are supporting demand, while four are pre-installation and another four await installation.

“Faster, more accurate gold analysis”Caption and image © Chrysos Corporation Limited. From “Pre AGM Trading Update Presentation”, 19 Nov 2026.
“YTD Activity (as at 19 November 2026).”Caption and image © Chrysos Corporation Limited. From “Pre AGM Trading Update Presentation”, 19 Nov 2026.

Chrysos signed 15 lease agreements during FY27, including 11 since its August results announcement, lifting total contracted units to 97. The new agreements include direct-to-miner contracts, four units with SGS, four with ALS and one with Alfred H Knight. The contracted pipeline now exceeds the company's target of 90 deployed units by the end of FY29, although converting signed contracts into operating revenue still depends on manufacturing and installation execution. The company previously reported record FY26 results, when its fleet stood at 46 deployed units and contracted units totalled 87.

Funding supports higher manufacturing cadence

Chrysos reported A$19.5 million in cash at 31 October, with A$80 million drawn and A$120 million undrawn under its A$200 million syndicated debt facility. It described the resulting A$139.5 million funding position as sufficient to support the increased manufacturing cadence required for further PhotonAssay deployments. The company also said it remained operating cash-flow positive.

The funding position gives the deployment plan room to expand, but it also leaves execution as the more immediate test. Chrysos is targeting manufacturing of 18 units a year and has said the lease pipeline provides a pathway to 90 deployed units by FY29. The next question is how quickly the 97 contracted units move through production, installation and utilisation.

Full-year guidance remains unchanged

Chrysos reaffirmed FY27 guidance of A$108 million to A$118 million in revenue and A$35 million to A$42 million in EBITDA, based on constant currency assumptions. The update is therefore a confirmation of the existing plan rather than an upgrade, despite the strong first four months and higher sample volumes.

That distinction matters. The figures are unaudited, and the company has not yet translated the early-year performance into higher full-year targets. Its 25 November annual general meeting will provide the next scheduled opportunity for management to discuss whether deployment timing, fleet utilisation and the mix between contracted payments and usage-based charges are tracking closely enough to support the ranges.

Bottom Line?

Chrysos has strong early operating momentum, but the investment case now turns on converting 97 contracted units into installed, revenue-generating equipment without stretching cash or debt capacity.

Questions in the middle?

  • How quickly will the 97 contracted units move from signed leases into deployed and operational PhotonAssay units?
  • Can Additional Assay Charges remain at an elevated share of revenue if mining activity or sample volumes soften?
  • Will the company maintain operating cash-flow positivity as manufacturing accelerates towards 18 units a year?

Sources